Feng Cheng Li

Orcid: 0000-0002-1846-639X

According to our database1, Feng Cheng Li authored at least 18 papers between 2020 and 2023.

Collaborative distances:
  • Dijkstra number2 of five.
  • Erdős number3 of four.

Timeline

Legend:

Book 
In proceedings 
Article 
PhD thesis 
Dataset
Other 

Links

Online presence:

On csauthors.net:

Bibliography

2023
DRESIS: the first comprehensive landscape of drug resistance information.
Nucleic Acids Res., January, 2023

DrugMAP: molecular atlas and pharma-information of all drugs.
Nucleic Acids Res., January, 2023

CovInter: interaction data between coronavirus RNAs and host proteins.
Nucleic Acids Res., January, 2023

2022
Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents.
Nucleic Acids Res., 2022

SYNBIP: synthetic binding proteins for research, diagnosis and therapy.
Nucleic Acids Res., 2022

VARIDT 2.0: structural variability of drug transporter.
Nucleic Acids Res., 2022

PFmulDL: a novel strategy enabling multi-class and multi-label protein function annotation by integrating diverse deep learning methods.
Comput. Biol. Medicine, 2022

Biological activities of drug inactive ingredients.
Briefings Bioinform., 2022

RNA-RNA interactions between SARS-CoV-2 and host benefit viral development and evolution during COVID-19 infection.
Briefings Bioinform., 2022

POSREG: proteomic signature discovered by simultaneously optimizing its reproducibility and generalizability.
Briefings Bioinform., 2022

ConSIG: consistent discovery of molecular signature from OMIC data.
Briefings Bioinform., 2022

2021
INTEDE: interactome of drug-metabolizing enzymes.
Nucleic Acids Res., 2021

GIMICA: host genetic and immune factors shaping human microbiota.
Nucleic Acids Res., 2021

2020
VARIDT 1.0: variability of drug transporter database (Corrigendum).
Nucleic Acids Res., 2020

VARIDT 1.0: variability of drug transporter database.
Nucleic Acids Res., 2020

NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data.
Nucleic Acids Res., 2020

Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics.
Nucleic Acids Res., 2020

Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.
Briefings Bioinform., 2020


  Loading...